Go to the list of all blogs
Abhoy Sarkar's Avatar
published in Blogs
Feb 20, 2026
Energy Recovery Inc. (ERII) Stock Analysis: Capitalizing on Rising Desalination Demand

Energy Recovery Inc. (ERII) Stock Analysis: Capitalizing on Rising Desalination Demand

Key Takeaways

  • ERII shares have remained resilient, trading near $15.47 ahead of Q4 and full-year 2025 earnings scheduled for February 25, 2026.

  • Q3 2025 results exceeded expectations, with revenue of $32 million and EPS of $0.07, despite year-over-year declines tied to project timing.

  • A $32.8 million contract award for Saudi Arabian desalination projects underscores strong global demand for ERII’s core technology.

  • Analysts maintain a Buy consensus with an average price target of $19.05, pointing to meaningful upside from current levels.

  • Management commentary and guidance in the upcoming earnings release will be critical sentiment drivers.

  • Expansion into CO₂ refrigeration systems provides a growing diversification opportunity beyond water infrastructure.

Market Snapshot

Energy Recovery Inc. (ERII) has traded steadily in recent weeks, holding in the mid-teens within its 52-week range of $10.86 to $18.32. The stock’s performance reflects investor confidence in its leadership position in energy recovery solutions, particularly as global water scarcity intensifies demand for desalination infrastructure. ERII currently carries a market capitalization of approximately $823 million and trades at a trailing P/E of 45.5, indicating premium valuation expectations tied to long-term growth.

Shares have remained above key technical support levels, with increased trading volume on positive sessions suggesting accumulation ahead of earnings. Investor focus remains centered on backlog strength, conversion timing, and forward guidance, as the company approaches a pivotal reporting period.

Recent Developments Influencing Share Performance

Energy Recovery’s recent price action has been shaped by a combination of earnings performance, contract wins, and analyst sentiment. The most notable development came on November 17, 2025, when the company announced nearly $33 million in contracts for its PX Pressure Exchanger devices across multiple seawater reverse osmosis (SWRO) plants in Saudi Arabia. These projects are expected to deliver more than 1.5 million cubic meters of fresh water per day, reinforcing ERII’s dominant position in the Gulf region and strengthening long-term revenue visibility.

Earlier, on November 5, 2025, ERII reported Q3 2025 results that surpassed consensus estimates. Revenue reached $32.0 million, beating expectations by roughly 7%, though declining 17% year over year due to project timing shifts. Gross margin remained strong at 64.2%, reflecting effective cost controls despite headwinds from product mix and tariffs. Net income totaled $3.9 million, or $0.07 per share, while operating expenses declined 6.4% year over year. The company ended the quarter with $79.9 million in cash, providing balance sheet flexibility.

While the earnings beat initially supported the stock, subsequent consolidation reflected investor sensitivity to revenue cadence. Management reiterated confidence in its full-year trajectory, noting improving quarterly progression and backlog conversion.

Analyst sentiment remains constructive. ERII carries a consensus Buy rating from four firms, with an average price target of $19.05—more than 20% above recent trading levels. Some analysts have highlighted the company’s CO₂ refrigeration technology as a longer-term growth catalyst, prompting higher targets of up to $23. Insider selling activity in late January and early February, conducted under 10b5-1 plans, was viewed as routine and had minimal impact on the stock. Additionally, the company’s $25 million share repurchase authorization announced in August 2025 continues to signal management’s confidence in intrinsic value.

On February 4, 2026, ERII confirmed that it will release Q4 and full-year 2025 results on February 25, refocusing attention on backlog updates and guidance. Shares have climbed approximately 7–8% in recent weeks, with gains supported by rising volume as investors position ahead of the report.

2026 Outlook and Key Factors to Watch

Looking into 2026, Energy Recovery’s outlook remains anchored by sustained growth in global desalination spending, particularly in water-stressed regions such as the Middle East and Asia. Consensus estimates project revenue growth of roughly 9% to $164.6 million, with EPS expected to rise more than 22% to $0.88, reflecting operating leverage and margin expansion.

Beyond water, CO₂ refrigeration systems represent a meaningful diversification opportunity, with early installations in North America demonstrating efficiency advantages over conventional technologies. Progress in commercial adoption could broaden ERII’s addressable market over time.

Key risks include variability in project timing, potential margin pressure from tariffs, and competitive dynamics in energy recovery technologies. Macro factors such as infrastructure investment cycles and sustainability-driven regulation will influence order flow. ERII’s strong balance sheet supports continued R&D investment and shareholder returns through buybacks.

Investors should closely monitor Q4 results for backlog trends, new contract announcements, milestones in CO₂ commercialization, and any revisions to analyst expectations following earnings. With exposure to water scarcity solutions and industrial efficiency, ERII remains well-positioned within long-term sustainability and energy transition themes.

Tickeron AI trading bot

Disclaimers and Limitations

Related Ticker: ERII

ERII in upward trend: price rose above 50-day moving average on July 31, 2026

ERII moved above its 50-day moving average on July 31, 2026 date and that indicates a change from a downward trend to an upward trend. In of 45 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on July 31, 2026. You may want to consider a long position or call options on ERII as a result. In of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for ERII just turned positive on August 03, 2026. Looking at past instances where ERII's MACD turned positive, the stock continued to rise in of 51 cases over the following month. The odds of a continued upward trend are .

The 10-day moving average for ERII crossed bullishly above the 50-day moving average on August 06, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ERII advanced for three days, in of 314 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 60 cases where ERII's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ERII declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

ERII broke above its upper Bollinger Band on August 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for ERII entered a downward trend on August 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ERII’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.362) is normal, around the industry mean (12.631). P/E Ratio (30.692) is within average values for comparable stocks, (84.340). ERII's Projected Growth (PEG Ratio) (0.000) is very low in comparison to the industry average of (2.020). ERII's Dividend Yield (0.000) is considerably lower than the industry average of (0.007). P/S Ratio (3.501) is also within normal values, averaging (229.120).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ERII’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.

Industry description

Companies in the industrial specialties industry process basic materials and minerals into various specialty products, such as flat and safety glass, fire retardant products, paints and coatings. Examples of companies operating in this industry are Sherwin-Williams Company, PPG Industries, Inc. and RPM International Inc.

Market Cap

The average market capitalization across the Industrial Specialties Industry is 2.44B. The market cap for tickers in the group ranges from 344.07K to 23.67B. VLTO holds the highest valuation in this group at 23.67B. The lowest valued company is ATMFF at 344.07K.

High and low price notable news

The average weekly price growth across all stocks in the Industrial Specialties Industry was -2%. For the same Industry, the average monthly price growth was -11%, and the average quarterly price growth was -15%. LIQT experienced the highest price growth at 12%, while RAIN experienced the biggest fall at -25%.

Volume

The average weekly volume growth across all stocks in the Industrial Specialties Industry was -4%. For the same stocks of the Industry, the average monthly volume growth was 46% and the average quarterly volume growth was 5%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 78
P/E Growth Rating: 76
Price Growth Rating: 65
SMR Rating: 87
Profit Risk Rating: 91
Seasonality Score: -15 (-100 ... +100)
View a ticker or compare two or three
ERII
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a developer of energy recovery devices

Industry IndustrialSpecialties

Profile
Details
Industry
Electrical Products
Address
1717 Doolittle Drive
Phone
+1 510 483-7370
Employees
230
Web
https://www.energyrecovery.com
Interact to see
Advertisement
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.
Gogo shares continue to trade near 52-week lows around $4, weighed down by competitive threats from Starlink and slower-than-anticipated AVANCE system upgrades. William Blair downgraded the stock to Market Perform in December 2025, citing leverage concerns and intensifying rivalry in in-flight connectivity.
Quantum Computing Inc. completed a $110 million acquisition of Luminar Semiconductor on February 2, significantly strengthening its photonics and manufacturing capabilities. Shares have traded with elevated volatility, peaking near $12.70 in mid-January before retreating to the $9 range amid heavy volume.
ERII shares have remained resilient, trading near $15.47 ahead of Q4 and full-year 2025 earnings scheduled for February 25, 2026. Q3 2025 results exceeded expectations, with revenue of $32 million and EPS of $0.07, despite year-over-year declines tied to project timing.